Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

GENE Relative to the S&P 500

GENE Relative to the Sector

Seasonal Chart Analysis

Analysis of the Genetic Technologies Ltd. (NASD:GENE) seasonal charts above shows that a Buy Date of January 1 and a Sell Date of March 25 has resulted in a geometric average return of 12.33% above the benchmark rate of the S&P 500 Total Return Index over the past 17 years. This seasonal timeframe has shown positive results compared to the benchmark in 12 of those periods. This is a good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 17 years by an average of 45.35% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women’s health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company’s revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.

To download GENE seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: GENE